Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Mar:128:98-101.
doi: 10.1016/j.ijid.2022.12.025. Epub 2022 Dec 26.

Time from last immunity event against infection during Omicron-dominant period in Malaysia

Affiliations
Multicenter Study

Time from last immunity event against infection during Omicron-dominant period in Malaysia

Su Lan Yang et al. Int J Infect Dis. 2023 Mar.

Abstract

Objectives: To study the incidence of Omicron infections in Malaysia and the exposures that could reduce the hazard of attaining Omicron infection.

Methods: We used a multicenter, prospective cohort to study 482 healthcare workers vaccinated with two and three doses of BNT162b2 for SARS-CoV-2 infection during the Omicron-dominant period in Malaysia.

Results: Between January 31 and July 31, 2022, the cumulative incidence was 44.6% (95% CI 40.2-49.1%), and the incidence rate was 3.33 (95% CI 2.91-3.80) per 1000 person-days. Our study found that protection against Omicron infection was significantly higher for persons with previous SARS-CoV-2 infection (hazard ratio [HR] 0.41, 95% CI 0.27-0.62) and persons with a more recent immunity event (<30 days [reference] vs >90 days, HR 3.82, 95%CI 1.34-10.90) from the beginning of the Omicron period.

Conclusion: Pre-Omicron natural infection and a recent immunity event protect against future Omicron infections.

Keywords: Healthcare workers; Hybrid immunity; Malaysia; Omicron; Previous SARS-CoV-2 infection; Vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve of cumulative incidence probability by pre-Omicron natural infection and time since last immunity event.

References

    1. World Health Organization. Tracking SARS-CoV-2 variants,, https://www.who.int/activities/tracking-SARS-CoV-2-variants; 2022 [accessed 29 October 2022].
    1. Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID's role in pandemic response. China CDC Wkly. 2021;3:1049–1051. doi: 10.46234/ccdcw2021.255. - DOI - PMC - PubMed
    1. Hodcroft EB. CoVariants: SARS-CoV-2 Mutations and Variants of Interest, http://covariants.org/; 2021 [accessed 21 July 2022].
    1. Lu L, Mok BWY, Chen LL, Chan JMC, Tsang OTY, Lam BHS, et al. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin Infect Dis. 2022;75:e822–e826. doi: 10.1093/cid/ciab1041. - DOI - PMC - PubMed
    1. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376:eabn4947. doi: 10.1126/science.abn4947. - DOI - PMC - PubMed

Publication types